Surveillance of HCC patients after liver RFA

Role of MRI with hepatospecific contrast versus three-phase CT scan - Experience of high volume oncologic institute

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and underwent MR and CT scans. All patients were enrolled in a research protocol that included CT with iodized contrast medium injection and MR with hepatospecific contrast medium injection. All patients were restaged within four weeks and at 3 months from ablation. The images were reviewed by four different radiologists to evaluate tumor necrosis, residual or recurrence disease, and evidence of new foci. Results. Thirty-two nodules were necrotic after treatment; 10 showed residual disease. Six new HCCs were identified. At first month followup CT has identified 34 necrotic lesions and 8 residual diseases; no new foci were recognized. At MRI instead, 32 complete necrotic lesions were identified, 10 lesions showed residual disease, and 2 new HCCs were found. At three months, CT demonstrated 33 completely necrotic lesions, 9 residual diseases, and 2 new HCCs. MR showed 31 complete necrotic lesions, 11 cases of residual disease, and 6 new HCCs. Conclusions. Hepatospecific contrast-enhanced MRI is more effective than multiphase CT in assessment of HCC treated with RFA.

Original languageEnglish
Article number469097
JournalGastroenterology Research and Practice
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Hepatocellular Carcinoma
Liver
Contrast Media
Injections
Residual Neoplasm
Necrosis
Recurrence
Research
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

@article{32228545504844088e5bf03a25ba568a,
title = "Surveillance of HCC patients after liver RFA: Role of MRI with hepatospecific contrast versus three-phase CT scan - Experience of high volume oncologic institute",
abstract = "Purpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and underwent MR and CT scans. All patients were enrolled in a research protocol that included CT with iodized contrast medium injection and MR with hepatospecific contrast medium injection. All patients were restaged within four weeks and at 3 months from ablation. The images were reviewed by four different radiologists to evaluate tumor necrosis, residual or recurrence disease, and evidence of new foci. Results. Thirty-two nodules were necrotic after treatment; 10 showed residual disease. Six new HCCs were identified. At first month followup CT has identified 34 necrotic lesions and 8 residual diseases; no new foci were recognized. At MRI instead, 32 complete necrotic lesions were identified, 10 lesions showed residual disease, and 2 new HCCs were found. At three months, CT demonstrated 33 completely necrotic lesions, 9 residual diseases, and 2 new HCCs. MR showed 31 complete necrotic lesions, 11 cases of residual disease, and 6 new HCCs. Conclusions. Hepatospecific contrast-enhanced MRI is more effective than multiphase CT in assessment of HCC treated with RFA.",
author = "Vincenza Granata and Mario Petrillo and Roberta Fusco and Setola, {Sergio Venanzio} and {De Lutio Di Castelguidone}, Elisabetta and Orlando Catalano and Mauro Piccirillo and Vittorio Albino and Francesco Izzo and Antonella Petrillo",
year = "2013",
doi = "10.1155/2013/469097",
language = "English",
volume = "2013",
journal = "Gastroenterology Research and Practice",
issn = "1687-6121",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Surveillance of HCC patients after liver RFA

T2 - Role of MRI with hepatospecific contrast versus three-phase CT scan - Experience of high volume oncologic institute

AU - Granata, Vincenza

AU - Petrillo, Mario

AU - Fusco, Roberta

AU - Setola, Sergio Venanzio

AU - De Lutio Di Castelguidone, Elisabetta

AU - Catalano, Orlando

AU - Piccirillo, Mauro

AU - Albino, Vittorio

AU - Izzo, Francesco

AU - Petrillo, Antonella

PY - 2013

Y1 - 2013

N2 - Purpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and underwent MR and CT scans. All patients were enrolled in a research protocol that included CT with iodized contrast medium injection and MR with hepatospecific contrast medium injection. All patients were restaged within four weeks and at 3 months from ablation. The images were reviewed by four different radiologists to evaluate tumor necrosis, residual or recurrence disease, and evidence of new foci. Results. Thirty-two nodules were necrotic after treatment; 10 showed residual disease. Six new HCCs were identified. At first month followup CT has identified 34 necrotic lesions and 8 residual diseases; no new foci were recognized. At MRI instead, 32 complete necrotic lesions were identified, 10 lesions showed residual disease, and 2 new HCCs were found. At three months, CT demonstrated 33 completely necrotic lesions, 9 residual diseases, and 2 new HCCs. MR showed 31 complete necrotic lesions, 11 cases of residual disease, and 6 new HCCs. Conclusions. Hepatospecific contrast-enhanced MRI is more effective than multiphase CT in assessment of HCC treated with RFA.

AB - Purpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and underwent MR and CT scans. All patients were enrolled in a research protocol that included CT with iodized contrast medium injection and MR with hepatospecific contrast medium injection. All patients were restaged within four weeks and at 3 months from ablation. The images were reviewed by four different radiologists to evaluate tumor necrosis, residual or recurrence disease, and evidence of new foci. Results. Thirty-two nodules were necrotic after treatment; 10 showed residual disease. Six new HCCs were identified. At first month followup CT has identified 34 necrotic lesions and 8 residual diseases; no new foci were recognized. At MRI instead, 32 complete necrotic lesions were identified, 10 lesions showed residual disease, and 2 new HCCs were found. At three months, CT demonstrated 33 completely necrotic lesions, 9 residual diseases, and 2 new HCCs. MR showed 31 complete necrotic lesions, 11 cases of residual disease, and 6 new HCCs. Conclusions. Hepatospecific contrast-enhanced MRI is more effective than multiphase CT in assessment of HCC treated with RFA.

UR - http://www.scopus.com/inward/record.url?scp=84890076857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890076857&partnerID=8YFLogxK

U2 - 10.1155/2013/469097

DO - 10.1155/2013/469097

M3 - Article

VL - 2013

JO - Gastroenterology Research and Practice

JF - Gastroenterology Research and Practice

SN - 1687-6121

M1 - 469097

ER -